ResearcherKumamoto UniversityActive in the last 2 years
Toru Takematsu
Matched on ORCID iD 0000-0003-4167-061X; OpenAlex author ID A5016969445. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 3 papers
Papers 5
- Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1002/ags3.70297↗
- High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection. Co-author DOI 10.1002/jhbp.70032↗
- Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in Pancreatic Ductal Adenocarcinoma After Pa… Co-author DOI 10.1097/mpa.0000000000002641↗
- Molecular Alterations Influencing the Prognostic Outcome in Small Pancreatic Cancer (≤2 cm). Co-author DOI 10.1097/mpa.0000000000002430↗
- Successful Treatment for the Recurrent Liver Metastases of the Pancreatic Cancer by Multimodality Therapy. Co-author DOI 10.1097/mpa.0000000000001622↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hiromitsu Hayashi · 5 shared papers, 2020–2026 · strength 1.19
- Paper Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for… DOI 10.1002/ags3.70297↗
- Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
- Paper Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in P… DOI 10.1097/mpa.0000000000002641↗
- Yuki Kitano · 4 shared papers, 2025–2026 · strength 1.08
- Paper Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for… DOI 10.1002/ags3.70297↗
- Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
- Paper Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in P… DOI 10.1097/mpa.0000000000002641↗
- Hirohisa Okabe · 3 shared papers, 2026 · strength 0.84
- Paper Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for… DOI 10.1002/ags3.70297↗
- Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
- Paper Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in P… DOI 10.1097/mpa.0000000000002641↗
- Masaaki Iwatsuki · 3 shared papers, 2026 · strength 0.84
- Paper Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for… DOI 10.1002/ags3.70297↗
- Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
- Paper Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in P… DOI 10.1097/mpa.0000000000002641↗
- Takanobu Yamao · 3 shared papers, 2020–2026 · strength 0.64
- Paper Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for… DOI 10.1002/ags3.70297↗
- Paper Molecular Alterations Influencing the Prognostic Outcome in Small Pancreatic Cancer (≤2 cm). DOI 10.1097/mpa.0000000000002430↗
- Paper Successful Treatment for the Recurrent Liver Metastases of the Pancreatic Cancer by Multimodality Therapy. DOI 10.1097/mpa.0000000000001622↗
- Takashi Matsumoto · 2 shared papers, 2026 · strength 0.57
- Paper Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for… DOI 10.1002/ags3.70297↗
- Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
- Shinsei Yumoto · 2 shared papers, 2026 · strength 0.55
- Paper High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Can… DOI 10.1002/jhbp.70032↗
- Paper Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in P… DOI 10.1097/mpa.0000000000002641↗
- Kosuke Mima · 2 shared papers, 2025–2026 · strength 0.52
- Shigeki Nakagawa · 2 shared papers, 2025–2026 · strength 0.52
- Norio Uemura · 2 shared papers, 2020–2026 · strength 0.38
- Paper Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in P… DOI 10.1097/mpa.0000000000002641↗
- Paper Successful Treatment for the Recurrent Liver Metastases of the Pancreatic Cancer by Multimodality Therapy. DOI 10.1097/mpa.0000000000001622↗
- Tatsunori Miyata · 1 shared paper, 2026 · strength 0.29
- Taishi Yamane · 1 shared paper, 2026 · strength 0.29
- Zhao Liu · 1 shared paper, 2026 · strength 0.28
- Yosuke Nakao · 1 shared paper, 2025 · strength 0.25
- Hideo Andreas Baba · 1 shared paper, 2025 · strength 0.25
- Hideo Baba · 1 shared paper, 2020 · strength 0.11
- Kensuke Yamamura · 1 shared paper, 2020 · strength 0.11
- Katsunori Imai · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.